$BCAX News

Bicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negative Head and Neck Cancer at ASCO Transcript

Bicara Therapeutics' Ficerafusp Alfa Plus Pembrolizumab Shows 31% Estimated 3-Year Overall Survival And Durable Responses In First-Line HPV-Negative Head And Neck Cancer Phase 1b Study

A Look At Bicara Therapeutics (BCAX) Valuation After Recent Share Price Pullback

Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet

Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back

Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data

Bicara Therapeutics Inc. (BCAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $18

Morgan Stanley Maintains Overweight on Bicara Therapeutics, Raises Price Target to $37

Bicara Therapeutics Inc (BCAX) Q1 2026 Earnings Call Highlights: Strategic Advances and ...

Guggenheim Initiates Coverage On Bicara Therapeutics with Buy Rating, Announces Price Target of $42

Bicara Therapeutics Q1 Earnings Call Highlights

Bicara Therapeutics (NASDAQ:BCAX) Q1 2026 Results Highlight Clinical Progress as EPS Misses Estimates

Bicara Therapeutics Inc. (BCAX) Q1 2026 Earnings Call Transcript

Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Bicara Therapeutics Q1 EPS $(0.93) Misses $(0.68) Estimate

Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000

Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET

A Look At Bicara Therapeutics (BCAX) Valuation After Earnings Losses And New Shelf Registration